Spruce Biosciences, Inc. Financing Receivable, Allowance for Credit Loss
Spruce Biosciences, Inc. (SPRB) had Financing Receivable, Allowance for Credit Loss of $0 as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Assets
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2023-05-15
- 2023-03-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2022-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
| Period end | Financing Receivable, Allowance for Credit Loss |
|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |